Personalized medicine vs guideline-based medicine

JAMA

Volumn 309, Issue 24, 2013, Pages 2559-2560

  Goldberger, Jeffrey J ^a   Buxton, Alfred E ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HEALTH CARE UTILIZATION; HUMAN; INTERMETHOD COMPARISON; PATIENT CARE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY;

EID: 84879393203     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.6629     Document Type: Short Survey

References (10)

1. VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions. Ann Intern Med. 2011;154(10):680-683.
2. President's Council of Advisors on Science and Technology. Priorities for Personalized Medicine. White House website. http://www.whitehouse.gov/files/ documents/ostp/PCAST/pcast-report-v2.pdf.
3. Moss AJ, Zareba W, Hall WJ, et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med . 2002;346(12):877-883. (Pubitemid 34984635)
4. Goldenberg I, Vyas AK, HallWJ, et al MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51(3):288-296.
5. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) [published correction appears in Circulation. 2009;120(5):e34-e35]. Circulation. 2008;117(21):e350-e408. (Pubitemid 351771339)
6. Goldberger JJ, Buxton AE, CainM, et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011;123(21):2423-2430.
7. Wilber DJ, Zareba W, Hall WJ, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109(9):1082-1084. (Pubitemid 38332609)
8. Hohnloser SH, Kuck KH, Dorian P, et al DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481-2488. (Pubitemid 39603155)
9. Steinbeck G, Andresen D, Seidl K, et al IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361(15):1427-1436.
10. Goldberger JJ,PassmanR. Implantable cardioverter-defibrillator therapy after acute myocardial infarction: the results are not shocking. J Am Coll Cardiol. 2009;54(22):2001-2005.